These are roughly equivalent to preventing and slowing the disease process in the mouse. We know that the incidence and prevalence of AD increases with increasing age over 65. It appears that the number of cases will triple in the next 30-40 years, if we do not find a way to slow it down or stop it. There are two strategies to attack AD progression. One is non specific therapy, directed at some aspect of the disease process that isn't specific for AD but is part of the problem.
Inflammation is an example.
Therefore, we need to try anti-inflammatory medications and see if they will slow the progression of disease. The other strategy is specific therapy, directed at the processes that occur in AD but not other diseases. Amyloid suppression therapy falls in this category. The prevalence of AD doubles every 5 years beginning at age 65. And this is a population which is very rapidly growing.